MYGN, the Next AMGN

[NY4Ever]

Piper raises target from 24 to 34.

[NY4Ever]

The big mystery, as I see it, is who is so stupid to sell this stock. Once again, in the last few minutes of trading a good buyer stepped in and took in quite a bit of stock at 27.50 while closing it within a penny of its high for the day. Stock continues to be under very smart accumulation. My target for the end of March is 30, end of June 40, end of year 60 and I am being very conservative.

[NY4Ever]

While most biotechs fell today, and some sharply, MYGN continues to show superb tape action. The stock continues under accumulation by very smart buyers. It is not too late to position this stock as the upside potential from current levels is 1000% and I consider the downside risk minimal. I have great expectations for the company's alzheimers drug, its 6287 cancer drug and its HIV drug. This stock is another AMGN. The weak sellers are out. The smart buyers are not trading this stock. Buy it and put it away for the next 5 years.

[NY4Ever]

UPDATE:


Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease
Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease

Flurizan Continues to Slow Decline in Cognition, Behavior and Daily Activities Through 21 Months

SALT LAKE CITY, U.T. -- March 16, 2006 -- Myriad Genetics, Inc. announced that data from its Phase 2 follow-on study of Flurizan™ in patients with mild Alzheimer's disease is being presented at the 19th annual meeting of the American Association of Geriatric Psychiatry.

The data suggest that study participants on 800 mg BID of Flurizan continued to demonstrate increasing benefit through month 21 in the area of cognition and memory loss and that they maintained more of their global function and activities of daily living than those on 400 mg BID of Flurizan or than the projected placebo.

Results of the p2 study and a summary of the 9-months of follow-on data were presented by Daniel Christensen, MD, Clinical Professor of Psychiatry, Clinical Professor of Neurology and Adjunct Professor of Pharmacology at the University Neuropsychiatric Institute, Salt Lake City, Utah.

The data suggest that during the follow-on period from months 12 to 21, the benefit of Flurizan on the measures of Alzheimer's disease increases in terms of both effect size and significance, the longer patients remain on Flurizan. The efficacy of Flurizan in the first 12 months of the Phase 2 was measured as the difference between the rates of decline, or slopes, of the treated groups and the placebo group.

In the follow-on study, because the placebo group has been randomized into the treatment arms, we are measuring the difference between the slopes of the treated groups and the slope of the placebo group during the first 12 months, extended through 21 months. The statistical significance of the resulting difference in slopes, or the effect size, is computed as a p value.

As measured by the performance of activities of daily living (ADCS-ADL), by patients taking 800 mg of Flurizan BID, there was a 52% effect size compared with the projected slope of the placebo at 21 months, with a significant value of P =.029. In terms of the patient's global function at 21 months, the CDR-sb scale showed a 75% effect size, with a value of P =.0007, also significant. These data suggest that there is a substantial benefit from Flurizan on activities of daily living and global function, and that the benefit is increasing over time.

The effect of Flurizan in improving cognitive decline, as measured on the ADAS-cog scale, has also increased, as shown by the effect size of 60% at 21 months. All three of the measures suggest sustained benefit from Flurizan in patients with mild Alzheimer's disease.

At 21 Months
Effect Size* (Significance, by slope analysis)
Activities of Daily Living 52% (P =.029)
Global Function 75% (P =.0007)
Cognition 60% (P =.096)
* Cohen's d

"The 21 months of data give us further confidence in the power of our Phase 3 trial to demonstrate a benefit from Flurizan for Alzheimer's patients," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "The results are additional evidence that Flurizan appears to be modifying the course of the underlying disease process."

About the Phase 2 Follow-on Study of Flurizan
After completion of Myriad's 12-month Phase 2 trial of Flurizan, study participants in Canada were given the option to continue in a follow-on study. A total of 81% of those participants opted to join the follow-on study. Those participants who had previously received placebo during the Phase 2 trial were randomized into the 400 mg BID group or the 800 mg BID group, and are therefore not included in the data presented during the follow-on study. Participants who were taking Flurizan in the initial Phase 2 trial continued on the same dose that they had been receiving. However, neither patients and their caregivers, nor their doctors, know which arm of the study the patients are in. During the Phase 2, the observed patient dropout rate was lower than anticipated by the study plan and that trend has continued through 21 months.

About Myriad's Phase 3 Trial of Flurizan in Alzheimer's Disease
Based on the positive Phase 2 results, Myriad is enrolling patients with mild Alzheimer's disease for a Phase 3 trial, at 130 centers across the United States. This enrollment is proceeding on schedule. The Phase 3 trial is a double blind, placebo-controlled trial. Patients will be randomized into one of two arms, receiving either 800 mg of Flurizan or placebo twice daily for the duration of the 12-month trial period. The study is designed to determine Flurizan's ability to reduce the rate of cognitive decline and activities of daily living in patients with mild Alzheimer's disease, as measured by the ADAS-cog test and the change in ADCS-ADL, respectively. Information on participation is available by calling (88 459-4888.

About Flurizan
Flurizan is the first in a new class of drug candidates known as Selective Amyloid beta-42 Lowering Agents (SALAs). Flurizan lowered levels of Abeta42 in cellular assays and animal models. Abeta42 is the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease. It is thought to be the key initiator of Alzheimer's disease, since Abeta42 has the greatest tendency to aggregate, cause neuronal damage and initiate amyloid deposits in the brain. Most genetic mutations that cause early-onset Alzheimer's disease appear to do so by increasing production of Abeta42. Myriad believes that Flurizan is the most advanced drug candidate that inhibits the production of Abeta42 to be evaluated in a clinical trial for the treatment of Alzheimer's disease.


Flurizan is a trademark of Myriad Genetics, Inc. in the United States and other countries.

[NY4Ever]

Ubs --- Buy

[NY4Ever]

UBS initiated buy today with 35 target just one more positive development.
But that is nothing compared to what will be announced prior to the end of June. On target for 30 this month. Like taking candy from a baby. Stock is a homerun.

[mrmarket]

UBS initiated buy today with 35 target just one more positive development.
But that is nothing compared to what will be announced prior to the end of June. On target for 30 this month. Like taking candy from a baby. Stock is a homerun.

Agreed..that would be consistent with what the rest of the financial services studs (GS, Bear) have been showing recently.

Good observation.

[gerihearne]

ubs

Agreed..that would be consistent with what the rest of the financial services studs (GS, Bear) have been showing recently.

Good observation.

are you talking about ubs ag ... kinda pricey ... 109.75 close ?

[Runner]

Here is longer-term chart (monthly)


Daily

[gerihearne]

excuse my ignorance ...

Here is longer-term chart (monthly)


Daily

Runner, I can't find ubs ... can you tell me what its full name is?

[thebign1]

Runner, I can't find ubs ... can you tell me what its full name is?

Hello Geri, UBS is the analyst & the chart is for MYGN.

regards, thebign1

[gerihearne]

dopey geri

Hello Geri, UBS is the analyst & the chart is for MYGN.

regards, thebign1

i am such a novice! thanks, thanks!!

[Adam]

NY4Ever

This has been a beautiful pick. I hope it continues just as you plan.

[DSteckler]

UBS is not an analyst per se, they're a banking and financial services group.

[NY4Ever]

This has been a beautiful pick. I hope it continues just as you plan.>>

You aint seen nothing yet.